Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

(2016) Igor Puzanov et al.   JOURNAL OF CLINICAL ONCOLOGY

Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study

(2016) Howard L. Kaufman et al.   Journal for ImmunoTherapy of Cancer

Talimogene Laherparepvec: First Global Approval

(2015) Sarah L. Greig   DRUGS

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Biosafety of Gene Therapy Vectors Derived From Herpes Simplex Virus Type 1

(2014) Filip Lim et al.   CURRENT GENE THERAPY

Diagnosis of genital herpes simplex virus infection in the clinical laboratory

(2014) Jérôme LeGoff et al.   Virology Journal

Phase I/II Study of Oncolytic HSVGM-CSF in Combination with Radiotherapy and Cisplatin in Untreated Stage III/IV Squamous Cell Cancer of the Head and Neck

(2010) K. J. Harrington et al.   CLINICAL CANCER RESEARCH

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

(2010) M. A. Curran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma

(2009) Howard L. Kaufman et al.   ANNALS OF SURGICAL ONCOLOGY

Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

(2009) Neil N. Senzer et al.   JOURNAL OF CLINICAL ONCOLOGY